Patrik Erlmann

Title: The Innovative Contributions of Patrik Erlmann

Introduction

Patrik Erlmann is a notable inventor based in Goetzens, Austria. He has made significant contributions to the field of oncolytic viruses, particularly through his innovative patents. With a total of 3 patents, Erlmann's work focuses on advancing cancer treatment methodologies.

Latest Patents

Erlmann's latest patents include groundbreaking inventions in the realm of recombinant rhabdoviruses. One of his notable patents is for a recombinant rhabdovirus encoding for CCL21. This invention relates to the use of oncolytic viruses, specifically a recombinant rhabdovirus, such as vesicular stomatitis virus, which encodes for a CCL21 protein. The invention aims to utilize this recombinant virus in cancer treatment and outlines methods for producing such viruses. Another significant patent is for a recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein. Similar to his previous work, this invention also focuses on the application of oncolytic viruses in cancer therapy and the production methods for these viruses.

Career Highlights

Throughout his career, Patrik Erlmann has worked with prominent companies in the biotechnology sector. He has been associated with Boehringer Ingelheim International GmbH and Viratherapeutics GmbH, where he has contributed to various innovative projects. His expertise in the field has allowed him to make substantial advancements in cancer research.

Collaborations

Erlmann has collaborated with notable professionals in his field, including Philipp Mueller and Klaus Erb. These collaborations have further enhanced his research and development efforts in oncolytic virus technology.

Conclusion

Patrik Erlmann's contributions to the field of oncolytic viruses and cancer treatment are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical science. His work continues to inspire future research and development in the biotechnology industry.